Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets PR Newswire - Tue Jul 28, 5:00PM CDT

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jul 24, 3:15PM CDT

SAN FRANCISCO , July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire - Tue Jul 21, 6:00AM CDT

Two global registrational Phase 3 trials initiated in ZENITH AD program

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jun 26, 3:30PM CDT

SAN FRANCISCO , June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Wed Jun 3, 3:15PM CDT

SAN FRANCISCO , June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York PR Newswire - Wed May 27, 5:15PM CDT

SAN FRANCISCO , May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare...

NKTR : 75.81 (+3.21%)
MarketBeat.com
Nektar Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 8, 6:07AM CDT

Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial...

NKTR : 75.81 (+3.21%)
Nektar: Q1 Earnings Snapshot AP - Thu May 7, 4:18PM CDT

Nektar: Q1 Earnings Snapshot

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports First Quarter 2026 Financial Results PR Newswire - Thu May 7, 3:15PM CDT

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.

NKTR : 75.81 (+3.21%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR PR Newswire - Thu May 7, 9:00AM CDT

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The...

NKTR : 75.81 (+3.21%)

Barchart Exclusives

Mark Zuckerberg Says Buyers Are Offering Meta a 'Significant Premium' for Its Compute — But He Turned Them Down, Calls Selling 'Foolish' Barchart - 19 minutes ago
Mark Zuckerberg recently told investors that other companies are trying to buy Meta Platforms' (META) computing power at a markup — and that he intends to keep most of it anyway. The subject came up on Meta's second-quarter earnings call on July 29, when an analyst asked how the company... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.